Course of treatment response in first-episode and chronic schizophrenia

American Journal of Psychiatry

Volumn 153, Issue 4, 1996, Pages 519-525

  Szymanski, Sally R ^a   Cannon, Tyrone D ^a   Gallacher, Fiona ^a   Erwin, Roland J ^a   Gur, Raquel E ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 0029989616     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.153.4.519     Document Type: Article

References (27)

1. Liddle PF, Barnes TRE: Syndromes of chronic schizophrenia. Br J Psychiatry 1990; 157:558-561
2. McGlashan TH, Fenton WS: The positive-negative distinction in schizophrenia: review of natural history validators. Arch Gen Psychiatry 1992; 49:63-72
3. Ram R, Bromet EG, Eaton WW, Pato C, Schwartz JE: The natural course of schizophrenia: a review of first admission studies. Schizophr Bull 1992; 18:182-207
4. Eaton WW, Thara R, Federman B, Melton B, Liang K: Structure and course of positive and negative symptoms in schizophrenia. Arch Gen Psychiatry 1995; 52:127-134
5. Lieberman JA, Alvir JMJ, Woerner M, Degreef G, Bilder RM, Ashtari M, Bogerts B, Mayerhoff DI, Geisler SH, Loebel A, Levy DL, Hinrichsen G, Szymanski S, Chakos M, Koreen A, Borenstein M, Kane JM: Prospective study of psychobiology in first-episode schizophrenia at Hillside Hospital. Schizophr Bull 1992; 18:351-371
6. Harvey PD, Davidson M, Powchik P, Schmeidler J, McQueeney R, Kaminsky R, Davis K: Time course and clinical predictors of treatment response in schizophrenia. Schizophr Res 1991; 5: 161-166
7. Stern RG, Kahn R, Davidson M: Predictors of response to neuroleptic treatment in schizophrenia. Psychiatr Clin North Am 1993; 16:313-338
8. Loebel AD, Lieberman JA, Alvir JMJ, Mayerhoff DI, Geisler SH, Szymanski SR: Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992; 149:1183-1188
9. Lo WH, Lo T: A ten year followup of Chinese schizophrenics in Hong Kong. Br J Psychiatry 1977; 131:63-66
10. May PR, Tuma AH, Dixon WJ, Yale C, Thiele DA, Kraude WH: Schizophrenia: a follow-up study of the results of five forms of treatment. Arch Gen Psychiatry 1981; 38:776-784
11. Wyatt RJ: Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991; 17:325-351
12. Altamura AC: A multidimensional (pharmacokinetic and clinical-biological) approach to neuroleptic response in schizophrenia with particular reference to drug resistance. Schizophr Res 1992; 8:187-198
13. Marder SR: Predictors of risk of relapse in schizophrenia, in Guidelines for Neuroleptic Relapse Prevention in Schizophrenia. Edited by Kissling W. Berlin, Springer-Verlag, 1991, pp 67-75
14. Gur RE, Mozley PD, Shtasel DL, Cannon TD, Gallacher F, Turetsky B, Grossman R, Gur RC: Clinical subtypes of schizophrenia: differences in brain and CSF volume. Am J Psychiatry 1994; 151:343-350
15. Spitzer RL, Williams JBW, Gibbon M: Structured Clinical Interview for DSM-III-R - Patient Version (SCID-P). New York, New York State Psychiatric Institute, Biometrics Research, 1986
16. Andreasen NC: Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, University of Iowa, 1984
17. Andreasen NC: Scale for the Assessment of Negative Symptoms (SANS). Iowa City, University of Iowa, 1984
18. Shtasel DL, Gur RE, Gallacher F, Heimberg C, Gur RC: Gender differences in the clinical expression of schizophrenia. Schizophr Res 1992; 7:225-231
19. Kaplan HI, Sadock BJ: Synopsis of Psychiatry, 6th ed. Baltimore, Williams & Wilkins, 1992, p 639
20. Gur RE, Mozley D, Resnick SM, Levick S, Erwin R, Saykin AJ, Gur RC: Relations among clinical scales in schizophrenia. Am J Psychiatry 1991; 148:472-478
21. Kane JM, Marder SR: Psychopharmacologic treatment of schizophrenia. Schizophr Bull 1993; 19:287-302
22. Herz MI, Glazer WM, Mostert MA, Sheard MA, Szymanski HV, Hafez H, Mirza M, Vana J: Intermittent vs maintenance medication in schizophrenia: two-year results. Arch Gen Psychiatry 1991; 48:333-339
23. Jolley AG, Hirsch SR, Morrison E: Trial of intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. Br J Psychiatry 1990; 301:837-842
24. Lieberman J, Koreen A: Neurochemistry and neuroendocrinology of schizophrenia: a selected review. Schizophr Bull 1993; 19:371-429
25. Meltzer HY: New drugs for the treatment of schizophrenia. Psychiatr Clin North Am 1993; 16:365-385
26. Segal DS, Kuczenski R: Behavioral pharmacology of amphetamine, in Amphetamine and Its Analogs: Psychopharmacology, Toxicology, and Abuse. Edited by Cho AK, Segal DS. Orlando, Fla, Academic Press, 1994, pp 115-150
27. Le Moal M, Simon H: Mesocorticolimbic dopaminergic network: functional and regulatory roles. Physiol Rev 1991; 71: 155-234